AR090544A1 - Metodo para tratar selectivamente a un sujeto que tenga cancer - Google Patents
Metodo para tratar selectivamente a un sujeto que tenga cancerInfo
- Publication number
- AR090544A1 AR090544A1 ARP130101029A AR090544A1 AR 090544 A1 AR090544 A1 AR 090544A1 AR P130101029 A ARP130101029 A AR P130101029A AR 090544 A1 AR090544 A1 AR 090544A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- cancer
- treating
- selectly
- pi3k
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 230000003197 catalytic effect Effects 0.000 abstract 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 2
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 abstract 1
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617284P | 2012-03-29 | 2012-03-29 | |
| US201361767848P | 2013-02-22 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090544A1 true AR090544A1 (es) | 2014-11-19 |
Family
ID=48083130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101029 AR090544A1 (es) | 2012-03-29 | 2013-03-27 | Metodo para tratar selectivamente a un sujeto que tenga cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9795596B2 (enExample) |
| EP (1) | EP2830621B1 (enExample) |
| JP (1) | JP6224067B2 (enExample) |
| KR (1) | KR20140138771A (enExample) |
| CN (1) | CN104271136A (enExample) |
| AR (1) | AR090544A1 (enExample) |
| AU (1) | AU2013241752B2 (enExample) |
| BR (1) | BR112014023530A2 (enExample) |
| CA (1) | CA2866127A1 (enExample) |
| CL (1) | CL2014002576A1 (enExample) |
| CO (1) | CO7091176A2 (enExample) |
| EA (1) | EA028984B1 (enExample) |
| EC (1) | ECSP14025016A (enExample) |
| ES (1) | ES2845560T3 (enExample) |
| GT (1) | GT201400206A (enExample) |
| HK (1) | HK1200723A1 (enExample) |
| IL (1) | IL234658B (enExample) |
| IN (1) | IN2014DN08970A (enExample) |
| MX (1) | MX2014011682A (enExample) |
| NZ (1) | NZ628596A (enExample) |
| PH (1) | PH12014502168A1 (enExample) |
| SG (2) | SG10201608001RA (enExample) |
| TW (1) | TW201345525A (enExample) |
| WO (1) | WO2013144249A1 (enExample) |
| ZA (1) | ZA201405938B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014229240B2 (en) * | 2013-03-15 | 2017-06-15 | Novartis Ag | Biomarkers of tumor pharmacodynamic response |
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| KR102486126B1 (ko) * | 2014-10-03 | 2023-01-09 | 노파르티스 아게 | 알펠리십을 포함하는 제약 조성물 |
| US20180353515A1 (en) * | 2015-12-03 | 2018-12-13 | Novartis Ag | Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna |
| WO2019199860A1 (en) * | 2018-04-09 | 2019-10-17 | The Research Foundation For The State University Of New York | Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| EP0425563B1 (en) | 1988-07-20 | 1996-05-15 | David Segev | Process for amplifying and detecting nucleic acid sequences |
| US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| EP2307414A4 (en) | 2008-07-07 | 2011-10-26 | Xcovery Holding Co Llc | SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
-
2013
- 2013-03-27 IN IN8970DEN2014 patent/IN2014DN08970A/en unknown
- 2013-03-27 AR ARP130101029 patent/AR090544A1/es unknown
- 2013-03-27 SG SG10201608001RA patent/SG10201608001RA/en unknown
- 2013-03-27 CN CN201380017393.0A patent/CN104271136A/zh active Pending
- 2013-03-27 EA EA201491787A patent/EA028984B1/ru not_active IP Right Cessation
- 2013-03-27 HK HK15101259.7A patent/HK1200723A1/xx unknown
- 2013-03-27 KR KR1020147026735A patent/KR20140138771A/ko not_active Ceased
- 2013-03-27 JP JP2015502341A patent/JP6224067B2/ja not_active Expired - Fee Related
- 2013-03-27 AU AU2013241752A patent/AU2013241752B2/en not_active Ceased
- 2013-03-27 NZ NZ628596A patent/NZ628596A/en not_active IP Right Cessation
- 2013-03-27 WO PCT/EP2013/056600 patent/WO2013144249A1/en not_active Ceased
- 2013-03-27 EP EP13715169.2A patent/EP2830621B1/en active Active
- 2013-03-27 CA CA 2866127 patent/CA2866127A1/en not_active Abandoned
- 2013-03-27 US US14/387,653 patent/US9795596B2/en not_active Expired - Fee Related
- 2013-03-27 BR BR112014023530A patent/BR112014023530A2/pt not_active IP Right Cessation
- 2013-03-27 ES ES13715169T patent/ES2845560T3/es active Active
- 2013-03-27 SG SG11201405169SA patent/SG11201405169SA/en unknown
- 2013-03-27 MX MX2014011682A patent/MX2014011682A/es unknown
- 2013-03-28 TW TW102111262A patent/TW201345525A/zh unknown
-
2014
- 2014-08-13 ZA ZA2014/05938A patent/ZA201405938B/en unknown
- 2014-09-15 IL IL234658A patent/IL234658B/en not_active IP Right Cessation
- 2014-09-26 PH PH12014502168A patent/PH12014502168A1/en unknown
- 2014-09-26 CL CL2014002576A patent/CL2014002576A1/es unknown
- 2014-09-29 CO CO14215143A patent/CO7091176A2/es unknown
- 2014-09-29 GT GT201400206A patent/GT201400206A/es unknown
- 2014-10-29 EC ECIEPI201425016A patent/ECSP14025016A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013241752B2 (en) | 2016-07-07 |
| SG10201608001RA (en) | 2016-11-29 |
| US20150111927A1 (en) | 2015-04-23 |
| ES2845560T3 (es) | 2021-07-27 |
| ZA201405938B (en) | 2015-11-25 |
| BR112014023530A2 (pt) | 2017-07-18 |
| CN104271136A (zh) | 2015-01-07 |
| AU2013241752A1 (en) | 2014-09-25 |
| EP2830621B1 (en) | 2020-10-21 |
| EA028984B1 (ru) | 2018-01-31 |
| IL234658B (en) | 2018-02-28 |
| IN2014DN08970A (enExample) | 2015-05-22 |
| CL2014002576A1 (es) | 2015-01-23 |
| US9795596B2 (en) | 2017-10-24 |
| GT201400206A (es) | 2017-09-28 |
| HK1200723A1 (en) | 2015-08-14 |
| EA201491787A1 (ru) | 2015-01-30 |
| KR20140138771A (ko) | 2014-12-04 |
| PH12014502168A1 (en) | 2014-12-10 |
| JP6224067B2 (ja) | 2017-11-01 |
| CO7091176A2 (es) | 2014-10-21 |
| TW201345525A (zh) | 2013-11-16 |
| JP2015514080A (ja) | 2015-05-18 |
| WO2013144249A1 (en) | 2013-10-03 |
| NZ628596A (en) | 2015-10-30 |
| CA2866127A1 (en) | 2013-10-03 |
| SG11201405169SA (en) | 2014-10-30 |
| MX2014011682A (es) | 2015-01-22 |
| ECSP14025016A (es) | 2015-09-30 |
| EP2830621A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| BR112013029330A8 (pt) | uso de anticorpo imunoconjugado maytansinoide anti-cd19 para o tratamento de sintomas de doenças de célula-b | |
| BR112018011272A2 (pt) | regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído | |
| WO2007103510A3 (en) | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders | |
| JOP20120246B1 (ar) | مركبات و تركيبات كمثبطات كيناز c-Kit | |
| MX374906B (es) | Nuevos inmunoconjugados | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| DOP2013000250A (es) | Composiciones de nucleasa terapeuticas y metodos | |
| CR20150114A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| AR090544A1 (es) | Metodo para tratar selectivamente a un sujeto que tenga cancer | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| MX2008013017A (es) | Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. | |
| CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |